Want to see MPLT full AI Analyst Report?
MPLT Stock Chart & Stats
$17.49
--
Market closed
$17.49
--
Day’s Range― - ―
52-Week Range$12.24 - $37.61
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.63K
Market Cap
$1.58B
Enterprise Value-$27.06M
Total Cash (Recent Filing)$310.11M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)―
Beta1.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,618,164
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit47.14
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$41.22Price Target Upside135.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthMapLight's extremely low leverage and sizable equity base provide durable financial flexibility for an early-stage biotech. This structure supports continued R&D spending without immediate liquidity pressure, allowing multi-quarter clinical programs to proceed before financing is required, preserving optionality.
Near-term Cash RunwayA cash balance near $400M that management expects to cover operations into 2027 materially reduces near-term financing urgency. This runway supports upcoming mid-stage readouts and additional enrollment without immediate dilution, enabling strategic development choices over the next 12–18 months.
Favorable Safety & Subgroup SignalsAlthough the primary endpoint was missed, clear safety/tolerability and prespecified subgroup benefits create a credible regulatory and commercial path for an irritability indication. Durable differentiation on safety versus D2 antipsychotics could support targeted labeling and a more de‑risked development route.
Bears Say
Widening Losses & Cash BurnLosses and operating cash burn roughly doubled year-over-year, indicating a structurally higher spend profile tied to multiple Phase 2 programs. If this elevated burn persists, it will materially increase financing needs and dilution risk within 12–24 months, pressuring long-term capital efficiency.
Missed Phase 2 Primary EndpointFailing the primary endpoint reduces the probability of broad label approval and raises development risk. Relying on subgroup signals requires additional targeted studies and regulator engagement, lengthening timelines and increasing costs versus a clear positive pivotal result.
Executive Turnover / CFO SeparationA sudden CFO separation introduces execution and governance uncertainty during a critical financing and clinical-data period. Interim leadership can maintain continuity, but sustained planning, investor communications, and complex financing decisions may be harder to execute without permanent senior finance leadership.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $12.24 and its highest was $37.61 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $1.58B.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 42,618,164 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.22 (135.69% Upside)
$41.22 (135.69% Upside)
Blogger Sentiment
Neutral
MPLT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 301.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $804.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-69.06%
Trailing 12-Months
Asset Growth
275.37%
Trailing 12-Months
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$41.22
▲(135.69% Upside)
Ownership Overview
63.47% Insiders
6.26% Mutual Funds
10.50% Other Institutional Investors
15.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---